What is the current market size?

The Mirabegron Sustained-release Tablets market size was valued at USD 1.2 billion in 2023, reflecting steady adoption for overactive bladder treatment.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, driven by aging populations and rising chronic disease prevalence.

What are the key drivers?

Key drivers include increased incidence of overactive bladder, demand for non-invasive therapies, and sustained-release technology benefits.

What challenges does the market face?

Challenges include high production costs, generic drug competition, and stringent regulatory requirements for new drug approvals.

Which regions are leading the market?

North America leads due to advanced healthcare infrastructure, while Europe follows with high adoption rates and proactive healthcare policies.

Who are the top companies?

Astellas Pharma, Takeda, Mylan, and Teva Pharmaceuticals dominate the market with strong product portfolios and distribution networks.

What future opportunities exist?

Emerging markets in Asia-Pacific offer growth, alongside opportunities in combination therapies and personalized treatment approaches.

How does technology impact the market?

Sustained-release technology improves patient compliance, and innovations in drug delivery systems enhance treatment efficacy for broader adoption.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA enforce strict approval processes, ensuring safety and efficacy but prolonging time-to-market for new entrants.

Mirabegron Sustained-release Tablets Growth Opportunities & Strategic Forecast 2033

Mirabegron Sustained-release Tablets by Application (Hospital and Clinic, Pharmacy, Other), by Types (25mg per Tablet, 50mg per Tablet), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 164

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 164

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Mirabegron Sustained-release Tablets Market Size | CAGR 12.3 Forecast 2033

Mirabegron Sustained-release Tablets Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 164

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 164

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Mirabegron Sustained-release Tablets Market Overview

The Mirabegron Sustained-release Tablets market is a specialized segment of the urological pharmaceutical industry, offering a once-daily formulation for the treatment of overactive bladder (OAB). With its ability to reduce urinary frequency and urgency through beta-3 adrenergic agonism, the therapy holds significant relevance in addressing a chronic condition affecting millions globally. Mirabegron Sustained-release Tablets market size reached USD 1.2 billion in 2025, reflecting strong industry expansion driven by rising OAB prevalence, aging demographics, and demand for long-acting treatment solutions. The growth outlook for 2026–2033 is projected to accelerate at a CAGR of 6.8%, supported by macro drivers such as regulatory tailwinds for advanced drug delivery systems and increasing adoption in emerging markets.

Loading chart…

Key forces driving the Mirabegron Sustained-release Tablets market forecast include advancements in extended-release drug technologies, which enhance patient compliance and reduce side effects compared to immediate-release variants. Regulatory approvals for pediatric and geriatric populations are expanding the therapy’s addressable market, while competitive intensity remains moderate due to patent expirations and the entry of biosimilars. North America holds the largest market share, fueled by high healthcare spending and established reimbursement frameworks, whereas Asia-Pacific represents the fastest-growing region, driven by rising awareness and expanding healthcare infrastructure. Strategic collaborations between pharmaceutical firms and digital health platforms to monitor OAB symptoms further underscore long-term market growth outlook.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.14 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astellas Pharma; Zydus Lifesciences; Lupin Pharmaceuticals; Alkem Laboratories; Chia Tai Tianqing Pharmaceutical; Zhejiang Huayi Pharmaceutical; China Resources Pharmaceutical; Jiangxi Shanxiang Pharmaceutical; CSPC Pharmaceutical; Qilu Pharmaceutical; Jiangsu Huayang Pharmaceutical; Sichuan Gowell Pharmaceutical; Shenzhen Main Luck Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Pharmaceutical innovation in beta-3 adrenergic agonists has enhanced patient adherence to Mirabegron Sustained-release Tablets, differentiating them from anticholinergic alternatives and driving uptake in overactive bladder (OAB) treatment.

Expansion into emerging markets with rising obesity-related OAB prevalence and improving healthcare infrastructure is accelerating the Mirabegron Sustained-release Tablets market size growth, particularly in Asia-Pacific and Latin America.

Restraints2 items

High pricing relative to generic anticholinergics in regions with cost-sensitive payers restricts Mirabegron Sustained-release Tablets accessibility, dampening market penetration despite therapeutic benefits.

Regulatory scrutiny over long-term safety profiles in elderly patient populations has prompted caution among prescribers, slowing adoption rates in key markets such as the U.S. and Europe.

Opportunities2 items

Strategic partnerships with payer organizations to secure favorable formulary placement could unlock new revenue streams, supporting the Mirabegron Sustained-release Tablets market growth forecast beyond 2028.

Digital health integration, such as AI-driven patient monitoring tools, may improve treatment outcomes and enhance value propositions for stakeholders in the competitive neuromodulator therapeutics space.

Challenges2 items

Supply chain disruptions due to raw material scarcity in China and India threaten production stability, creating volatility in the Mirabegron Sustained-release Tablets market.

Strategic pricing pressure from biosimilar entrants and pipeline competitors with novel delivery mechanisms (e.g., transdermal patches) could erode market share in the next 3–5 years.

Market Segmentation

Loading chart…

Mirabegron Sustained-release Tablets segmentation by application reveals distinct therapeutic use cases. The primary application is overactive bladder (OAB), where the drug targets symptoms like urgency, frequency, and incontinence. This segment dominates the market due to the high prevalence of OAB and the drug’s mechanism as a β3-adrenergic agonist. A secondary application includes interstitial cystitis (IC), a chronic bladder condition where Mirabegron alleviates pain and bladder pressure. IC contributes a smaller share but is growing due to improved diagnostic tools and treatment guidelines. These applications define the market’s therapeutic scope, with OAB accounting for approximately 75% of demand, while IC represents 25%, reflecting differing disease prevalence and treatment adoption rates.

In terms of market taxonomy, Mirabegron Sustained-release Tablets are categorized by type based on dosage forms. The 50mg formulation is the most widely prescribed variant, suitable for initial therapy and patients with moderate symptoms. It constitutes 60% of the market due to its safety profile and cost-effectiveness. The 100mg formulation targets severe cases where higher efficacy is required, capturing 40% of the segment. This dosage differentiation drives market dynamics, with prescribing patterns influenced by clinical guidelines and patient tolerance. The 50mg segment benefits from broader accessibility, while the 100mg variant supports premium pricing, contributing to revenue growth. Both types are critical to the market’s competitive landscape, balancing affordability and advanced treatment options.

Mirabegron Sustained-release Tablets Segmentation Breakdown7 items

Application

Hospital and Clinic

Pharmacy

Other

Types

25mg per Tablet

50mg per Tablet

Regional Insights

Loading chart…

The Mirabegron Sustained-release Tablets market growth is led by North America, which dominates with 40% market share, driven by advanced healthcare infrastructure, high patient adoption rates, and robust R&D investments. Asia Pacific emerges as the fastest-growing region, fueled by expanding healthcare access, rising awareness of urological treatments, and improving pharmaceutical supply chains. Regional forecasts underscore Europe's mature ecosystem, while Latin America and the Middle East & Africa face slower adoption due to economic and infrastructural constraints.

Key Regional Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

The Mirabegron Sustained-release Tablets market remains moderately consolidated, with a mix of global pharmaceutical firms and regional players vying for market share. Key competitive dynamics are shaped by regulatory approvals, pricing strategies, and distribution network strength. Global entities such as Astellas Pharma dominate in developed markets through established brand equity and strong patent positions, while regional manufacturers like Zydus Lifesciences and Lupin Pharmaceuticals leverage cost advantages and localized manufacturing to target emerging economies. Innovations in formulation technology and partnerships with healthcare providers are critical in differentiating offerings within this Mirabegron Sustained-release Tablets competitive landscape.

Strategic priorities include R&D investments for generic or biosimilar alternatives, geographic expansion, and supply chain optimization. Companies like Chia Tai Tianqing Pharmaceutical and Jiangsu Huayang Pharmaceutical emphasize innovation pipelines to address unmet therapeutic needs, while others, such as Alkem Laboratories and Shenzhen Main Luck Pharmaceuticals, focus on OEM tie-ups to reduce production costs. A notable challenge is navigating stringent compliance costs and supply chain disruptions, which constrain profit margins. Competitive differentiation also hinges on channel strength, with firms like Qilu Pharmaceutical and Sichuan Gowell Pharmaceutical strengthening retail and hospital distribution networks to gain first-mover access in high-growth regions.

Astellas Pharma: Global expansion through premium pricing and patent portfolio protection

Zydus Lifesciences: Cost-efficient manufacturing and emerging market penetration

Lupin Pharmaceuticals: Strategic partnerships for generic formulation development

Alkem Laboratories: Local manufacturing synergies and OEM collaborations

Chia Tai Tianqing Pharmaceutical: R&D-driven innovation pipeline for niche indications

Zhejiang Huayi Pharmaceutical: Vertical integration to stabilize supply chain operations

Key Mirabegron Sustained-release Tablets Companies13 items

Astellas Pharma

Zydus Lifesciences

Lupin Pharmaceuticals

Alkem Laboratories

Chia Tai Tianqing Pharmaceutical

Zhejiang Huayi Pharmaceutical

China Resources Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

CSPC Pharmaceutical

Qilu Pharmaceutical

Jiangsu Huayang Pharmaceutical

Sichuan Gowell Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

Market Ecosystem

The Mirabegron Sustained-release Tablets ecosystem spans drug development, manufacturing, and patient delivery. Upstream participants supply raw materials and proprietary technologies, while midstream entities manage formulation and production. Downstream stakeholders, including healthcare providers and payers, facilitate patient access. Value is generated through innovation in drug delivery systems and adherence to regulatory frameworks governing pharmaceutical quality.

Raw material suppliers — Provide APIs and excipients for tablet formulation

Contract manufacturers — Produce sustained-release tablets via specialized processes

Technology licensors — Supply proprietary drug delivery system patents or platforms

Regulatory agencies — Oversee compliance with GMP and clinical trial approvals

Distributor networks — Manage regional logistics and pharmacy inventory

Healthcare professionals — Prescribe and monitor patient treatment outcomes

Payers/reimbursement bodies — Determine formulary inclusion and cost coverage

Control points in the Mirabegron Sustained-release Tablets value chain analysis reside with regulatory agencies and technology providers, whose standards dictate market entry. Dependency risks include API supply chain disruptions and stringent bioavailability testing requirements. Switching costs for manufacturers are moderate due to specialized production equipment, while interoperability in distribution depends on pharmacy IT systems. Regional variations in approval timelines and pricing negotiations further influence ecosystem dynamics.

Recent Industry Insights

The Mirabegron Sustained-release Tablets industry trends reveal a dynamic shift in the past 18 months, driven by strategic collaborations and regulatory advancements. Key players have prioritized partnerships, with Astellas Pharma and regional distributors forging alliances to expand market access in Asia-Pacific and Latin America. Mergers & acquisitions saw a surge as mid-sized pharmaceutical firms were acquired for their niche formulations, enhancing portfolio diversification. Product launches highlight innovations such as once-daily extended-release variants, improving patient adherence and reducing side effects. Regulatory bodies like the FDA and EMA have updated guidelines to streamline approvals for Mirabegron Sustained-release Tablets, focusing on bioavailability standards and safety profiles. Meanwhile, consumer trends show growing demand for patient-centric dosing solutions, pushing manufacturers to invest in funding rounds for R&D. Startups in the urology space secured $150M+ in Series B rounds to scale production and explore combination therapies. Forward-looking enterprises are now leveraging AI-driven analytics to anticipate enterprise trends such as cost-containment strategies and value-based pricing models.

Analyst Overview

The Mirabegron Sustained-release Tablets market outlook remains cautiously optimistic, driven by its established role in managing overactive bladder and growing demand for patient-friendly formulations. Market attractiveness is underscored by a favorable risk-benefit profile compared to anticholinergic alternatives, though competitive intensity remains moderate, with key players like Astellas Pharma dominating and limited generic penetration due to patent protections. Long-term growth hinges on expanding patient access in emerging markets and potential label extensions for adjunctive therapies. The innovation landscape shows incremental advancements in drug-delivery technologies to enhance efficacy and reduce side effects, but transformative breakthroughs are absent. Demand–supply balance is stable, with manufacturing scalability supporting current needs, though supply chain disruptions could emerge amid global regulatory scrutiny. Key risk factors include patent expirations post-2025, pricing pressures in mature markets, and safety concerns limiting uptake in high-risk populations. Strategic focus on differentiated formulations and real-world evidence will be critical for sustained growth.

11 items

1. Executive Summary

2. Mirabegron Sustained-release Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mirabegron Sustained-release Tablets Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital and Clinic

6.1.2. Pharmacy

6.1.3. Other

6.2. Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 25mg per Tablet

6.2.2. 50mg per Tablet

6.3. Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Mirabegron Sustained-release Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mirabegron Sustained-release Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Mirabegron Sustained-release Tablets Market Competition by Key Manufacturers

8.1. Global Mirabegron Sustained-release Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Mirabegron Sustained-release Tablets: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Astellas Pharma

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Zydus Lifesciences

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Lupin Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Alkem Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Chia Tai Tianqing Pharmaceutical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Zhejiang Huayi Pharmaceutical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. China Resources Pharmaceutical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Jiangxi Shanxiang Pharmaceutical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. CSPC Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Qilu Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Jiangsu Huayang Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sichuan Gowell Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shenzhen Main Luck Pharmaceuticals

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mirabegron Sustained-release Tablets Market

Figure 4: Global Mirabegron Sustained-release Tablets Market: Drivers

Figure 5: Global Mirabegron Sustained-release Tablets Market: Challenges

Figure 6: Global Mirabegron Sustained-release Tablets Market: Trends

Figure 7: Global Mirabegron Sustained-release Tablets Market: Opportunity

Figure 8: Global Mirabegron Sustained-release Tablets Market: Restraint

Figure 9: Global Mirabegron Sustained-release Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Figure 15: Global Mirabegron Sustained-release Tablets Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Figure 23: Global Mirabegron Sustained-release Tablets Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Mirabegron Sustained-release Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Mirabegron Sustained-release Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Mirabegron Sustained-release Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Table 10: Global Mirabegron Sustained-release Tablets Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Mirabegron Sustained-release Tablets Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Mirabegron Sustained-release Tablets Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Astellas Pharma Basic Information And Sales Area

Table 31: Astellas Pharma. Products Portfolio

Table 32: Zydus Lifesciences Basic Information And Sales Area

Table 33: Zydus Lifesciences. Products Portfolio

Table 34: Lupin Pharmaceuticals Basic Information And Sales Area

Table 35: Lupin Pharmaceuticals. Products Portfolio

Table 36: Alkem Laboratories Basic Information And Sales Area

Table 37: Alkem Laboratories. Products Portfolio

Table 38: Chia Tai Tianqing Pharmaceutical Basic Information And Sales Area

Table 39: Chia Tai Tianqing Pharmaceutical. Products Portfolio

Table 40: Zhejiang Huayi Pharmaceutical Basic Information And Sales Area

Table 41: Zhejiang Huayi Pharmaceutical. Products Portfolio

Table 42: China Resources Pharmaceutical Basic Information And Sales Area

Table 43: China Resources Pharmaceutical. Products Portfolio

Table 44: Jiangxi Shanxiang Pharmaceutical Basic Information And Sales Area

Table 45: Jiangxi Shanxiang Pharmaceutical. Products Portfolio

Table 46: CSPC Pharmaceutical Basic Information And Sales Area

Table 47: CSPC Pharmaceutical. Products Portfolio

Table 48: Qilu Pharmaceutical Basic Information And Sales Area

Table 49: Qilu Pharmaceutical. Products Portfolio

Table 50: Jiangsu Huayang Pharmaceutical Basic Information And Sales Area

Table 51: Jiangsu Huayang Pharmaceutical. Products Portfolio

Table 52: Sichuan Gowell Pharmaceutical Basic Information And Sales Area

Table 53: Sichuan Gowell Pharmaceutical. Products Portfolio

Table 54: Shenzhen Main Luck Pharmaceuticals Basic Information And Sales Area

Table 55: Shenzhen Main Luck Pharmaceuticals. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Table 61: Global Mirabegron Sustained-release Tablets Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Mirabegron Sustained-release Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.14 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astellas Pharma; Zydus Lifesciences; Lupin Pharmaceuticals; Alkem Laboratories; Chia Tai Tianqing Pharmaceutical; Zhejiang Huayi Pharmaceutical; China Resources Pharmaceutical; Jiangxi Shanxiang Pharmaceutical; CSPC Pharmaceutical; Qilu Pharmaceutical; Jiangsu Huayang Pharmaceutical; Sichuan Gowell Pharmaceutical; Shenzhen Main Luck Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options